BetterLife Scales up Manufacturing of AP-003 (Interferon Alpha 2b) to Prepare for Clinical Trials

BetterLife Pharma Inc. | September 17, 2020

BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAT) an emerging biotech company, today announced it has entered into an agreement with List Biological Laboratories, Inc. (“List Labs”) for the manufacture of its proprietary interferon alpha 2b for the treatment of COVID-19. "Following our recent merger, we are proud to be continuing the development of Altum Pharmaceutical’s proprietary interferon alpha 2b inhalation for treatment of COVID-19. We look forward to working with List Labs to bring this treatment to patients as quickly as possible as we prepare for our imminent trials in Australia" said BetterLife's Chief Executive Officer, Dr. Ahmad Doroudian. Under the terms of the agreement, List Labs will provide manufacturing services from its state-of-the-art biological development and cGMP manufacturing facility in Campbell, California.

Spotlight

AIST is one of the largest public research institutes in Japan.
AIST conducts research and development in a variety of fields including environment, energy, life science, biotechnology, information technology, electronics, nanotechnology, materials, manufacturing, metrology, measurement science, geological survey, and applied geoscience.

Spotlight

AIST is one of the largest public research institutes in Japan.
AIST conducts research and development in a variety of fields including environment, energy, life science, biotechnology, information technology, electronics, nanotechnology, materials, manufacturing, metrology, measurement science, geological survey, and applied geoscience.

Related News

MEDICAL

NiKang Therapeutics Completes $200 Million Series C Financing to Advance Highly Differentiated Small Molecules Addressing Difficult-to-Drug Targets

NiKang Therapeutics | May 31, 2021

NiKang Therapeutics Inc., a clinical-stage biotech company focused on developing innovative small molecule oncology medicines to assist patients with unmet medical needs; today announced the completion of an oversubscribed $200 million Series C financing led by Cormorant Asset Management, HBM Healthcare Investments, and Octagon Capital Advisors with participation from a premier syndicate of funds, including new investors EcoR1 Capital, Perceptive Advisors, Wellington Management, Ally Bridge Group, Pavilion Capital, funds and accounts managed by BlackRock, RA Capital Management, Surveyor Capital (a Citadel company), Samsara BioCapital, PFM Health Sciences, Invus, Janus Henderson Investors and Logos Capital. All existing investors, including CBC Group, RTW Investments, LP, Lilly Asia Ventures, Matrix Partners China, and Casdin Capital, participated in the financing. About the funding, Bing Yao, Ph.D., former CEO and chairman of Viela Bio, and Ting Jia, Ph.D., founder and chief investment officer of Octagon Capital Advisors, will join NiKang’s Board of Directors. “We are thrilled to have such an outstanding group of investors as our shareholders,” said Zhenhai Gao, Ph.D., co-founder, president, and chief executive officer of NiKang. “Their support of our vision allows us to build the world’s leading precision oncology company. We are now well-positioned to rapidly advance our pipeline into the clinic, including our differentiated HIF-2 alpha inhibitor, and to bring our company to the next level of growth.” “This financing is a testament to the quality of our science and team,” Kelsey Chen, Ph.D., MBA, chief financial officer, added. “Since joining NiKang, I have witnessed the passion and dedication of a group of talented scientists who are devoting their lives to advancing treatments for patients. We are grateful to be recognized by such a high-caliber group of investors.” “NiKang has made remarkable progress over the last eight months since our initial investment,” said Ting Jia, Ph.D., a chief investment officer of Octagon. “We are impressed by the team’s accomplishment. We believe NiKang’s unique approach to attacking difficult-to-drug targets offers promising opportunities to develop breakthrough treatments for cancer patients. We are excited to co-lead the series C financing and partner with the NiKang team to accelerate its growth.” “We are proud of what NiKang has achieved since its inception,” said Sean Cao, executive chairman of NiKang and managing director of CBC Group, which incubated the company. “The strength of this group of investors validates NiKang’s achievements and demonstrates their confidence in NiKang’s potential to grow into a leading innovative drug company.” Proceeds will be used to advance the company’s lead drug candidates into the clinic, expand the pipeline, and fund internal drug discovery programs. About NiKang Therapeutics NiKang Therapeutics is a clinical-stage biotech company focused on discovering and developing innovative small molecule oncology medicines to assist patients with unmet medical needs. Our target selection is driven by deep insights into disease biology and molecular pathways. Our discovery approach is informed by target structure biology and capitalizes on structure-based drug design. The successful implementation of our strategy enables us to rapidly and efficiently discover and advance proprietary drug candidates with the most desirable pharmacological features into clinical studies. We strive to bring transformative medicines to patients in need.

Read More

MEDICAL

AvantGen Announces Licensing of its anti-SARS-CoV-2 Antibody Clones to IGM Biosciences for COVID-19 Therapy Development

AvantGen | January 12, 2021

AvantGen, Inc., a San Diego-based biotechnology organization with a variety of innovation stages for neutralizer revelation and enhancement, and novel NK and T cell engager age, today reported permitting of a board of its anti-SARS-CoV-2 antibody clones to IGM Biosciences for COVID-19 therapy development. Utilizing its novel yeast show framework and huge different human antibody response libraries, AvantGen has distinguished a board of high partiality human monoclonal antibody clones that quandary to two unmistakable epitopes on the receptor restricting space of the SARS-CoV-2 spike protein. After official, the antibodies block the spike protein from cooperating with ACE2 and subsequently forestall infection prompted cell-slaughtering, otherwise called cytopathic impact. Furthermore, one gathering of immune response clones can likewise obstruct ACE2's cooperation with SARS-CoV-1, showing that the epitope perceived by this gathering of clones is rationed between SARS-CoV-1 and - 2, conceivably presenting more extensive killing action against this family of coronaviruses. In a recognized animal model of SARS-CoV-2 contamination, AvantGen's lead applicant antibody has been appeared to fundamentally diminish viral load in, and macrophage infiltration of, the lungs, as well as reduce disease severity.

Read More

CELL AND GENE THERAPY

Research Demonstrates Novel HIT Receptor Enhances T cell Antigen Sensitivity and Elicits Superior Tumor Control

Mnemo Therapeutics | January 24, 2022

The journal Nature Medicine recently published a study in which researchers developed a novel receptor to enhance recognition of tumors by engineered T cells, addressing an underlying cause for relapsed tumors in patients after chimeric antigen receptor therapy. The study demonstrates high antigen sensitivity of HLA-independent T-cell receptors, created by editing the TCR Alpha Constant chain locus in human peripheralbio blood Tcells. Low antigen expression One major limitation of CARs is antigen escape, when a tumor no longer expresses the antigen detectable by the CARs or expresses them at a very low level; CARs with heightened sensitivity to low-expression level antigens boosts the efficacy of otherwise promising T-cell therapies. In the study, conducted by researchers at New York's Memorial Sloan Kettering Cancer Center, researchers produced HIT T-cells and analyzed them in animal models HIT T-cells were engineered from human peripheral blood T-cells by inserting variable region genes in the TRAC locus, endowing the cell with a single specificity for a target antigen such as CD19. Notably, this sensitivity was shown to be higher than traditional CARs for low levels of antigen expression resulting in superior cytotoxicity and cytokine secretion. HIT Tcells outperformed traditional CAR T-cells in vivo in mouse models of B cell leukemia and acute myeloid leukemia, without costimulation. Coexpression of HIT with CD80 and 4-1BBL further augmented therapeutic activity and mouse survival. HIT T-cells are a promising therapy for targeting cancer cell surface antigens with low abundance due to their sensitivity and persistence. The team responsible for this important work includes MSKCC researcher and Mnemo Therapeutics scientific cofounder Michel Sadelain, M.D., Ph.D., MSKCC researcher and Mnemo scientific advisor Isabelle Rivière, Ph.D., as well as Justin Eyquem, Ph.D., University of California San Franciso and Mnemo scientific cofounder. Mnemo's EnfiniT Platform These findings support Mnemo's EnfiniT platform as the next-generation toolkit for CAR-T immunotherapies, which are founded on decades of breakthrough research from Institut Curie and MSKCC, and supported with best-in-class T-cell manufacturing. The EnfiniT platform brings together a suite of technologies to address the key challenges associated with CAR T therapies by both identifying a new class of antigens with greater tumor specificity and applying a range of technologies to significantly improve T-cell memory, persistence and sensitivity. The goal is to dramatically improve the body's ability to fight and overcome disease. About Mnemo Therapeutics Mnemo Therapeutics is a biotechnology company focused on the development of powerful new cell therapies. With its EnfiniT platform, Mnemo applies a novel, integrated approach to T-cell therapy to transform the body's immune response to overcome disease. Mnemo is headquartered in Paris with an office in New York City, and it maintains state of the art laboratories in Paris, New York, and Princeton, New Jersey. The company leverages an international talent pool and global resources in its quest to create accessible cures for all patients in need.

Read More